HEPATOCELLULAR CARCINOMA

This early-stage study tests a new drug called SIM0610 in about 260 adults with advanced solid tumors (e.g., lung, colorectal, head and neck, liver cancer) that have spread. The main goals are to check the drug's safety and find the right dose, while also looking for signs that i…

This study tests if memantine, a drug used for Alzheimer's, can help control advanced liver cancer in people with severe cirrhosis. About 12 adults with liver cancer that cannot be surgically removed will take memantine alone. Researchers will track how long the cancer stays stab…

This study tests whether a new drug called rilvegostomig, combined with standard treatments, helps people with advanced liver cancer live longer. About 1220 adults whose cancer cannot be removed or treated with local therapies will receive either the new combination or the curren…

This study tests whether combining the drug regorafenib with a type of internal radiation (Y-90) can control advanced liver cancer that cannot be removed by surgery. About 30 adults with unresectable hepatocellular carcinoma will receive the combination. The goal is to see how ma…

This study tests a combination of two types of drugs (anti-PD-1/PD-L1 and anti-VEGF) in 50 adults with advanced liver cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and can shrink tumors or slow cancer growth. Participants mu…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests a new treatment called RP2, a virus that attacks cancer cells and boosts the immune system, combined with other drugs for people with advanced liver or bile duct cancer that has not responded to first-line therapy. About 60 adults will receive RP2 alone or with s…

This study tests a new experimental drug called CVM-1118 combined with the immunotherapy nivolumab in people with advanced liver cancer that cannot be surgically removed. The goal is to see if the combination shrinks tumors or slows cancer growth. About 95 adults aged 18 and olde…

This study tests a new treatment plan for people with advanced liver cancer that has either spread to a few other spots or formed a blood clot in the main liver vein. The treatment combines chemotherapy directly into the liver artery, two immunotherapy drugs, and targeted radiati…

This study tests whether giving chemotherapy directly into the liver plus an immunotherapy drug (tislelizumab) before surgery, followed by more immunotherapy after surgery, can prevent liver cancer from coming back in high-risk patients. About 39 adults with liver cancer that is …

This study tests whether adding a targeted drug (zanzalintinib) to two immunotherapy drugs (durvalumab and tremelimumab) can shrink tumors in people with advanced liver cancer that cannot be removed by surgery. About 40 adults who have not had prior systemic therapy will particip…

This study tests a two-step treatment for people with advanced liver or stomach cancer whose disease got worse after immunotherapy. First, a drug called tirapazamine is injected directly into the liver tumor's blood supply, then patients receive nivolumab, an immunotherapy drug. …

This early-phase study tests a new type of immunotherapy for adults with solid tumors that have a specific marker called GPC3. The treatment involves taking a patient's own T cells, adding genes to help them recognize and attack cancer cells, and then giving them back. The study …

This study is for adults with liver cancer that still has active tumors or has come back after a previous treatment called TARE. Researchers want to see if a precise type of radiation called carbon ion radiotherapy can safely shrink or control these remaining tumors. About 48 par…

This study tests a combination of drugs (cabozantinib, ipilimumab, nivolumab) and a procedure called TACE in 35 adults with liver cancer that cannot be removed by surgery or treated with a transplant. The goal is to see if this approach can stop the cancer from growing for at lea…

This study is for people with liver cancer who have had surgery to remove their tumor but are at high risk of the cancer returning. Researchers want to see if adding a procedure called TACE (which delivers chemotherapy directly to the liver) after surgery can help keep the cancer…

This study tests a high-precision radiation treatment called SBRT in 139 adults with liver cancer who are waiting for a liver transplant but cannot receive standard bridging treatments like radiofrequency ablation or chemoembolization. The goal is to see if SBRT can safely contro…

This study tests a single injection of IP-001 given right after surgery or ablation for liver cancer (hepatocellular carcinoma). The goal is to see if it can safely delay or prevent the cancer from returning. About 126 adults with high-risk liver cancer will take part and be foll…

This study tests a personalized vaccine made from a patient's own immune cells combined with an immunotherapy drug (nivolumab) to prevent liver cancer or colorectal cancer that has spread to the liver from returning after surgery. About 60 adults with these cancers will receive t…

This study tests an experimental oral drug called Alintegimod combined with standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if the com…

This study tests a drug called 177Lu-PSMA-617 in people with advanced liver cancer that has spread. The drug delivers radiation directly to cancer cells that have a specific marker (PSMA). The trial will enroll 10 adults whose cancer has worsened after standard treatment, to see …

This study is for people with liver cancer that has spread into the main vein of the liver (portal vein tumor thrombus) and can still be removed by surgery. The goal is to see if giving a combination of radiation, an immunotherapy drug (camrelizumab), and a targeted therapy pill …

This study tests a drug called cabozantinib in 20 adults whose liver cancer came back after a liver transplant. The goal is to see if the drug can control the cancer and slow its growth. Participants take the drug until it stops working or side effects become too severe.

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This study compares a three-drug combination (durvalumab, tremelimumab, and lenvatinib) against a two-drug combination (durvalumab and tremelimumab) in people with advanced liver cancer that cannot be removed by surgery. About 140 adults who have not had prior treatment for their…

This study tests whether adding a drug that blocks a cancer cell survival process (autophagy) can make standard TACE therapy work better for liver cancer. TACE cuts off blood supply to the tumor, but cancer cells often survive by eating themselves. The new approach aims to kill m…

This early-stage study tests whether adding targeted radiation (SBRT) to a standard immunotherapy combination (atezolizumab and bevacizumab) is safe and effective for people with advanced liver cancer that cannot be treated with surgery. About 18 participants will receive the tre…

This study tests a new treatment called C-CAR031 for people with advanced or recurrent liver cancer that has not responded to at least two prior therapies. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. …

This study tests whether adding a precise type of radiation (carbon ion radiotherapy) to standard immunotherapy drugs (atezolizumab and bevacizumab) can better control advanced liver cancer. About 52 adults with liver cancer that cannot be surgically removed will receive this com…

This study tests a combination of four drugs (cyclophosphamide, sorafenib, bevacizumab, and atezolizumab) in children and young adults with solid tumors that have come back or not responded to treatment. The goal is to find safe doses and see if the drugs shrink tumors. The trial…

This study tests whether a newer, ultrasound-guided endoscopic procedure can better prevent repeat bleeding from enlarged veins in the stomach or esophagus compared to standard endoscopic treatments. The trial enrolls 84 adults with liver cancer who have recently had such bleedin…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to at least two other therapies. The treatment uses specially engineered immune cells to attack cancer cells. The goal is to find a safe dose and see if it can shrink tumor…

This study tests a combination of three drugs—atezolizumab, bevacizumab, and memantine—in people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink tumors. About 19 adults with newly diagnosed, untreated liver cancer…

This study tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, in 32 people with advanced liver cancer who also have moderate cirrhosis (Child-Pugh-B). The main goal is to see if this treatment is safe and tolerable. The study focuses on including underse…

This early-phase study tests a new drug called ZW251 in people with advanced liver cancer, a type of lung cancer, or certain germ cell tumors. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The main goals are to check safety and find the righ…

This early-phase study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatm…

This study tests whether combining two drugs (atezolizumab and bevacizumab) with a type of internal radiation (Y-90) can shrink liver tumors enough to allow patients to get a liver transplant. It involves 40 adults with liver cancer who either need to shrink their tumor to qualif…

This study tests whether adding a cancer vaccine (UCPVax) to standard treatment (atezolizumab and bevacizumab) can shrink tumors better than standard treatment alone in people with advanced liver cancer that cannot be removed by surgery. About 105 adults who have not had prior sy…

This study is for people with a single liver tumor (hepatocellular carcinoma) who are scheduled for surgery. The goal is to see if giving a short course of high-precision radiation before the operation is safe and does not cause delays or serious side effects that would prevent s…

This study tests whether taking prednisone before and during radiation therapy can reduce liver inflammation in people with liver cancer. About 20 participants will take prednisone for a short time around their radiation sessions. The goal is to see if this approach lowers the ri…

This early-phase study tests a new treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a specific marker called GPC3. The treatment is given after a short course of chemotherapy. The main goal is to see if this…

This study looks at whether giving the immunotherapy drug tislelizumab at different infusion times after surgery can help prevent liver cancer from coming back in high-risk patients. About 33 adults aged 18-75 with early-stage liver cancer who had curative surgery will take part.…

This early-stage study tests a new drug, BAY 3547926, that delivers a small amount of radiation directly to liver cancer cells. It is for people with advanced hepatocellular carcinoma (HCC) that has a specific protein called GPC3. The goal is to find a safe dose and see if the dr…

This early-stage trial tests a new type of immunotherapy for children and young adults with certain solid tumors that have come back or not responded to treatment. The therapy uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer c…

This early-stage trial tests a new drug called MT-303 in about 70 adults with advanced liver cancer that has spread or cannot be removed. The study aims to find a safe dose and see if the drug works, both alone and with other cancer medicines. Participants must have a specific ma…

This study tests whether adding a liver-directed chemotherapy (GEMOX) to standard immunotherapy (durvalumab + tremelimumab) works better than immunotherapy alone for people with advanced liver cancer that has a high tumor burden. About 196 adults with liver cancer that has spread…

This early-stage study tests a new drug called JMT106 in 200 adults with advanced solid tumors (such as lung or liver cancer) who have tried other treatments without success. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Parti…

This study tests whether combining two or three drugs (cabozantinib, durvalumab, and tremelimumab) can safely shrink tumors in people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that cannot be removed by surgery will …

This study tests whether giving two drugs (sintilimab and bevacizumab) before surgery can lower the chance of liver cancer coming back. It involves 37 adults with resectable liver cancer that is beyond standard transplant criteria. The goal is to see if this approach improves 1-y…

This study tests whether adding a precise form of radiation (SBRT) to standard drug therapy helps people with advanced liver cancer (BCLC stage C) live longer. About 184 adults aged 18-70 with good liver function will be randomly assigned to receive either drug therapy alone or d…

This study is testing whether combining two drugs, Envafolimab and Lenvatinib, can shrink tumors in people with advanced solid tumors like lung, kidney, or liver cancer. About 170 adults whose cancer has worsened after standard treatments will receive the drug combination. The go…

This study is testing an experimental drug called MGC026 in about 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Participants receive the drug by IV and are closely monitore…

This study is for people with advanced liver cancer that cannot be removed by surgery and who also have severe cirrhosis (Child-Pugh B7 or B8). It tests the safety of two drugs, atezolizumab and bevacizumab, given together or alone as a first treatment. The goal is to see if this…

This study tests a drug called tirapazamine given with a procedure that blocks blood flow to liver tumors (embolization). The goal is to find the safest dose and see how well it shrinks tumors. It is for people with liver cancer or certain metastatic tumors that have spread to th…

This study tests a treatment for advanced liver cancer that delivers chemotherapy directly to the liver through a small tube, combined with a temporary blocking agent (lipiodol) to trap the drugs in the tumor. The goal is to shrink tumors while keeping the liver working well. Abo…

This study tests whether giving a combination of radiation beads (SIRT) and two immunotherapy drugs (tremelimumab and durvalumab) before surgery is safe and effective for people with liver cancer that can be removed. About 20 participants will receive the treatment and then have …

This study tests a new medicine called PF-08634404, given alone or with another drug (ipilimumab), for adults with advanced liver cancer that cannot be removed by surgery. The goal is to check safety and see if the treatment shrinks tumors. About 138 participants will receive the…

This study tests a new drug, AK112, alone or with other treatments, for people with advanced liver cancer. The first part checks safety and the best dose, while the second part compares how well it works against standard therapies. About 280 participants will take part to see if …

This study tests a drug called enfortumab vedotin in people with advanced colorectal or liver cancer that has spread or cannot be removed. Participants must have already tried at least one standard treatment. The goal is to see if the drug can shrink tumors or slow the disease. A…

This study tests whether adding immunotherapy (atezolizumab) and a targeted drug (bevacizumab) before and after standard heat ablation can prevent liver cancer from returning. About 202 adults with small, early-stage liver tumors will be randomly assigned to receive ablation alon…

This study tests a drug called ADI-PEG 20 against a placebo in 300 people with advanced liver cancer that cannot be removed by surgery and who have high levels of the amino acid arginine in their blood. The goal is to see if the drug helps people live longer. Participants must ha…

This study tests whether giving an immune-boosting drug (PD-1 inhibitor) after standard microwave ablation can keep early-stage liver cancer from returning. About 200 adults with early liver cancer will receive the drug after ablation and be followed for recurrence and side effec…

This study tests new immune-boosting drugs, alone or with other cancer treatments, in people with advanced liver or bile duct cancer. The goal is to see if these drugs can shrink tumors or slow cancer growth. About 294 adults whose cancer has spread or cannot be removed by surger…

This study monitors the safety and effectiveness of two drugs, Imjudo and Imfinzi, in 246 liver cancer patients in Korea. It observes patients already receiving these drugs as part of their normal care, without adding new treatments. The goal is to see how well the drugs work and…

This early-phase study tests a new treatment approach for people with advanced liver cancer. It combines freezing the tumor (cryoablation) with a drug infusion into the liver (SD-101) and two immunotherapy drugs (durvalumab and tremelimumab). The main goal is to check safety and …

This early-stage study tests a new treatment called C-CAR031 for people with advanced liver cancer that cannot be removed by surgery. The therapy uses the patient's own immune cells, modified to better attack cancer cells. The main goals are to see if it is safe and whether it ca…

This early-stage study tests a new drug, QXL138AM, for safety in about 100 people with advanced solid tumors (like ovarian, pancreatic, lung, or breast cancer) or multiple myeloma. Participants must have tried other treatments without success. The study will find the right dose a…

This study tests whether adding two liver-directed treatments (chemoembolization and artery infusion) to standard immunotherapy can shrink tumors better in people with advanced liver cancer that cannot be removed by surgery. About 55 adults with good liver function and performanc…

This study tests an experimental pill called TTI-101 in people with advanced liver cancer that cannot be removed by surgery. Some participants receive TTI-101 alone, while others get it combined with standard immunotherapy drugs. The main goals are to check safety and see if the …

This study tests a new drug called AZD9793 for people with advanced liver cancer that has spread. The drug is an antibody designed to help the body's immune cells attack cancer cells. The main goals are to check if the drug is safe and to see if it can shrink tumors. About 304 ad…

This study tests a new way to treat advanced liver cancer by using artificial intelligence to find the best dose of three drugs (sorafenib, sonidegib, and irinotecan) for each patient. The goal is to make treatment more effective while reducing side effects. About 12 adults with …

This study is testing whether a new PET imaging tracer called [18F]FAPI-74 can find tumors as well as or better than the standard tracer in adults with certain cancers (like pancreatic, ovarian, or lung cancer). Participants will get both types of scans to compare how many tumors…

This study tests whether a new type of ultrasound can find liver cancers that standard ultrasound often misses. About 328 adults at risk for liver cancer will get both standard and new ultrasound scans. The goal is to catch more cancers early, when they are easier to treat.

This study tests whether contrast-enhanced ultrasound (CEUS) can more accurately show if liver cancer has been killed by a targeted radiation treatment called TARE. Standard CT or MRI scans often take months to give clear results, delaying next steps. Researchers will enroll 30 a…

This study tests whether a fast, no-dye MRI scan can find liver cancer earlier than the standard ultrasound in 300 people with cirrhosis who are at high risk. Participants will get both scans every 6 months for 2.5 years. The goal is to see if the MRI catches cancers that ultraso…

This study aims to develop a blood test that uses tiny particles called exosomes and machine learning to help doctors accurately tell apart two common types of liver cancer—hepatocellular carcinoma and cholangiocarcinoma—before surgery. Researchers will collect blood samples from…

This early-phase study is testing whether a special PET-CT scan using a tracer called PYLARIFY (piflufolastat F18) can better detect cancer that has spread in people with pancreatic cancer, liver cancer, or breast cancer. About 36 adults will receive the scan, and doctors will co…

This study is testing a new blood test algorithm called GAAD to see if it can find liver cancer earlier in people with liver cirrhosis. Current methods often catch the cancer too late, leaving few treatment options. The study will compare the GAAD test with standard tests in 600 …

This study tests whether a shorter, safer MRI scan can find returning liver cancer as well as the usual CT scan. It involves 455 adults who have been cancer-free for at least two years after treatment. The goal is to reduce radiation and contrast dye risks while still catching ca…

This study compares standard ultrasound monitoring to ultrasound plus a short, 10-minute MRI (Fast-MRI) for detecting early-stage liver cancer in people with cirrhosis who are at high risk. About 944 participants will be followed for several years to see which method finds more e…

This study tests whether a special nutrition drink taken before liver surgery can improve patients' nutritional status and reduce complications. About 100 adults with liver tumors who are scheduled for major liver surgery will be randomly assigned to receive either the special dr…

This study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it at the clinic. About 50 adults with various cancers will try both ways to see which they prefer and how it affects their quality of life. The goal is to reduce the time, cost, …

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if patients prefer home care and if it is safe. Participants will receive their usual cancer drugs either at home or in the clini…

This study tests whether a mushroom extract called Antrodia cinnamomea can help liver cancer patients recover liver function and feel better after a procedure called TACE (chemoembolization). About 60 adults with liver cancer will take the extract or a placebo for 28 days after T…

This study tests whether a dietary supplement called β-alanine can reduce fatigue in people with advanced liver cancer who are receiving standard immunotherapy. About 158 participants will take either β-alanine or a placebo alongside their regular treatment. The main goal is to s…

This early-phase study tests whether a special PET scan (18F-FSPG) can help guide treatment for liver cancer (hepatocellular carcinoma). About 60 participants will receive standard Y90 radioembolization therapy, and researchers will compare scan results with blood markers (ctDNA)…

This pilot study aims to see if taking a blood sample from the vein that drains directly from a liver or pancreatic tumor can detect more cancer DNA than a standard blood draw from the arm. Fifteen adults scheduled for a tumor biopsy will provide both types of blood samples. The …

This study looks at 300 liver cancer patients who cannot have surgery and are receiving a treatment called TACE. Researchers will use artificial intelligence to analyze routine CT scans taken before treatment, measuring body composition to predict survival and treatment outcomes.…

This study aims to find genetic and immune system clues that may lead to liver cancer in people with fatty liver disease or alcohol-related liver damage. Researchers will study 710 adults, both with and without cirrhosis, to understand early changes that happen before cancer deve…

This study monitors patients who have already received at least one dose of Replimune's experimental cancer therapy (RPx) for up to 5 years. The goal is to identify any delayed side effects or infections related to the treatment. No new drugs are given—participants simply provide…

This study looks at a method called 'Teaching the Teachers' to see if it helps spread guidelines for diagnosing liver cancer. Researchers will train expert radiologists, who then teach other doctors. The goal is to see if this approach increases how often the guidelines are used …

This study aims to uncover the genetic and molecular causes of liver cancer in children. Researchers will analyze DNA, gene activity, and other markers from up to 1,600 participants, including children with liver tumors and their biological relatives. The goal is to better classi…

This study tracks 20 adults with chronic hepatitis delta (a serious liver infection) who are starting a new drug called bulevirtide. Researchers want to see how the drug changes the gut's bacteria and bile acids over 48 weeks, and how those changes relate to inflammation and live…

This study looks at how often a specific gene change (BAP1 mutation) is found in people with certain cancers like eye melanoma, skin melanoma, kidney cancer, and others. Researchers will study 500 patients and their family members to understand cancer patterns and risk factors. T…

This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA) can predict if liver cancer will come back after surgery. Researchers will measure ctDNA before and after surgery, and at 3 and 6 months, in 150 adults with liver cancer. The goal is to see i…

This study creates tiny, lab-grown copies of liver tumors from 150 patients to better understand liver cancer and test how well different treatments might work. Participants will have their tumor samples collected during surgery, but no new treatment is given. The goal is to lear…

This study is testing whether growing a patient's tumor cells in the lab (called organoids) can help doctors choose the most effective drugs. Researchers will take a small biopsy from 40 people with advanced liver or colorectal cancer that no longer responds to standard treatment…

This study looks at why some people with liver cancer are diagnosed late. Researchers will survey 730 patients about things like transportation, food, and housing that may make it hard to get early cancer care. They will also interview doctors and community leaders to understand …

This study is measuring a protein called Galectin-3 in the blood of 300 people with kidney, bladder, lung, or liver cancer who are starting immunotherapy. The goal is to see if higher levels of this protein are linked to worse treatment outcomes or more side effects. Researchers …

This study looks at medical records from 15,000 people with chronic liver diseases (like hepatitis, fatty liver, or cirrhosis) to understand how these conditions affect other body systems. Researchers will track new cases of liver cancer and serious liver complications over time.…

This study aims to identify biological markers (biomarkers) that can predict outcomes in people with advanced liver cancer treated with the immunotherapy drugs tremelimumab and durvalumab. Researchers will follow 120 participants who have not had prior systemic treatment and are …

This study is testing two new scoring methods (PLEASE and M10S20) to predict serious liver problems like liver failure or liver cancer in 600 people with advanced chronic liver disease. Participants are split into two groups: one gets standard check-ups every 6 months, while the …

This study is looking at whether a protein called Glypican-3, found in the blood, can help predict how well a common immunotherapy combination (Atezolizumab plus Bevacizumab) works in people with advanced liver cancer. Researchers will measure Glypican-3 levels before and during …

This study looks back at the medical records of 2000 people with liver cancer in Guangxi, China, who received treatment before surgery (called conversion or neoadjuvant therapy). The goal is to find out which treatments work best and which patients benefit the most. Researchers w…

This study is collecting data from 1500 people with liver tumors who are getting a treatment called thermal ablation, which uses heat to destroy cancer. Researchers will use artificial intelligence to analyze this data to find the best ways to plan and evaluate the treatment. The…

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…

This study aims to understand how the immune system and genes change in people with advanced liver cancer during immunotherapy. Researchers will collect blood and tumor samples from 50 participants before, during, and after treatment. The goal is to find biomarkers that predict h…